Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1

Conditions

Mesothelioma 3Pleural Effusion, Malignant 1Neoplasms 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Mesothelioma, Malignant 1Cholangiocarcinoma 1Carcinoma 1Adenocarcinoma 1

Interventions

aldesleukin 2Trastuzumab 2Pharmaceutical Preparations 2Interleukin-2 2Carboplatin 2Bevacizumab 2tocilizumab 1tipifarnib 1romidepsin 1lipoplatin 1Verteporfin 1Valacyclovir 1Tyrosine Kinase Inhibitors 1Sorafenib 1SPI-77, liposomal 1Povidone-Iodine 1Pleurodesis 1Photochemotherapy 1Paclitaxel 1LMB-100 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunotherapy, Adoptive 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Decitabine 1Dasatinib 1Cytoreduction Surgical Procedures 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pleural Effusion, Malignant × LMB-100 × Clear all
NCT05375825 2024-02-02

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
MyeloidOther solid neoplasmThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Mesothelioma, Malignant, Carcinoma, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡